Please select the option that best describes you:
What are your top takeaways in Lymphoma from ASH 2025?
Answer from: Medical Oncologist at Academic Institution
The EPCORE FL-1 trial randomized patients to R2 vs. epcoritamab-R2. This study indicated that the addition of the CD20/C3 bispecific antibody, epcoritamab, to rituximab and lenalidomide could potentially establish a new standard, given the dramatic improvement in remission duration as compared to ...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
Here are my top 3 oral presentations from the 2025 ASH meeting (2 for FL and 1 for DLBCL):Primary results from the EPCORE FL-1 phase 3 study of Epcor + len + R vs R2 in patients with R/R FL: Fixed duration of Epcor + len + R showed 79% reduction in the risk of disease progression and death with high...
Answer from: Medical Oncologist at Community Practice
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial — This trial may change practice by using the combination of BTK-I and Ven without CD20 antibodies. This time-limited option led to MRD, and I would ex...